Analysis of Reliability and Applicability of PGT-M for Monogenic Disease Screening in Kyrgyzstan

Opening: Patient Misconception

A 32-year-old woman carrying a gene variant for spinal muscular atrophy (SMA) repeatedly asked during consultation: "Can Kyrgyzstan detect SMA? Is the technology there more backward than in China?" Her biggest worry was "you get what you pay for," but she hesitated due to the long waiting times and high costs for third-generation IVF in China. This dual mindset of "technical doubt + cost anxiety" is very common among those considering PGT-M in Kyrgyzstan. In reality, the issue is not about the "country" but the "specific center" — different reproductive institutions in the same city can have vastly different laboratory qualifications and genetic counseling capabilities.

I. Direct Answer to the Question

Whether PGT-M for monogenic disease screening in Kyrgyzstan is reliable cannot be generalized. The core of reliability depends on three conditions:

• Whether the laboratory has international accreditation (e.g., CAP, CLIA, or ISO 15189).
• Whether next-generation sequencing (NGS) technology is used, rather than only FISH or PCR.
• Whether a genetic counselor interprets pathogenic variants and designs personalized probes.

Centers meeting the above conditions can achieve a PGT-M accuracy rate of 97%–99% (depending on the type of pathogenic gene and whether SNP haplotype analysis is performed). If a center only claims "we can do it" without providing any technical documents or case data, caution is advised.

II. Why Does the "Reliability" Question Arise?

The assisted reproduction industry in Kyrgyzstan has developed rapidly since 2019, with several reproductive centers in Bishkek established as joint ventures with Russia and Turkey. However, PGT-M (preimplantation genetic testing for monogenic diseases) requires extremely high technical standards, involving:

• Clear diagnosis of the pathogenic gene in the proband or parents (a genetic report is mandatory).
• Whole genome amplification after embryo biopsy.
• Construction of family haplotypes to exclude contamination and chromosomal abnormalities.

Some small centers can only provide PGT-A (aneuploidy screening) but advertise it as "PGT-M," resulting in limited actual testing scope. This leads to negative impressions of "unreliability" after user experiences.

III. What Doctors Say

An embryologist who studied in Moscow and now works at a reproductive center in Bishkek pointed out: "PGT-M is not 'send us embryos and we can test.' We need patients to provide a complete pathogenic gene report, and ideally whole blood samples from both parents or affected children." If the gene mutation is unclear or family samples cannot be obtained, probes cannot be designed even with the best laboratory equipment. He advises: "Send us your genetic test report from China or abroad first for evaluation. Only after confirming a testing plan can we proceed."

IV. Comparison of Differences Between Countries

V. Differences Between Hospitals — Checklist Before Choosing

Public hospitals in Kyrgyzstan generally do not perform PGT-M; it is mainly available at private centers. The following are three types:

• High-level international joint venture centers (e.g., cooperation with Turkish or European institutions): CAP accredited, traceable data, embryo biopsy performed by full-time embryologists, report turnaround time about 5–7 days.
• Local mid-range centers: Equipment updated relatively quickly, but genetic counselors may be outsourced, leading to insufficient experience in probe design for rare diseases (e.g., PCD, BBS).
• Small clinics: Only offer PGT-A, claim to do PGT-M but actually refer samples to third-party laboratories in Russia, increasing the risk of sample loss or contamination during transfer.

VI. Most Common Pitfalls

Pitfall 1: Gene report does not confirm pathogenicity. Many users receive a "genetic test report" that only shows carrier status but lacks pathogenicity classification according to ACMG guidelines. PGT-M requires a clear pathogenic (Pathogenic/Likely Pathogenic) gene. If the report only indicates "variant of uncertain significance (VUS)," no conclusion can be drawn after embryo testing.

Pitfall 2: Ignoring the risk of false negatives due to mosaicism. Embryo biopsy extracts 5–8 cells. If the embryo has low-level mosaicism, it may test normal but develop abnormally. Some centers in Kyrgyzstan do not routinely recommend subsequent amniocentesis for verification; users should proactively request it.

Pitfall 3: Assuming one PGT-M test can rule out all genetic diseases. PGT-M only targets a known single gene. If a couple carries different pathogenic genes (e.g., SMA + deafness gene), separate testing plans must be designed, doubling the cost and time.

VII. Actual Process

From consultation to transfer, PGT-M in Kyrgyzstan generally involves 6 steps:

1. Remote Genetic Evaluation: Send genetic reports and pedigree charts (if available) of both partners and the proband to the center's genetics department.
2. Probe Design and Pre-Experiment: The center's laboratory designs SNP haplotype probes based on the pathogenic gene and validates them using family DNA. Takes 2–4 weeks.
3. Ovarian Stimulation and Egg Retrieval: The woman travels to Kyrgyzstan to begin ovarian stimulation (about 10–14 days).
4. Intracytoplasmic Sperm Injection (ICSI): To avoid sperm contamination of maternal DNA.
5. Embryo Biopsy and Whole Genome Amplification: Culture to blastocyst stage (day 5–6), extract 5–8 trophectoderm cells.
6. NGS Sequencing and Genetic Counseling Report: Results available in about 7–10 working days, selecting embryos free of the pathogenic gene and chromosomally normal.

VIII. Frequently Asked Questions

Q1: Can PGT-M in Kyrgyzstan test for mitochondrial diseases?

Most centers cannot. Mitochondrial disease inheritance is complex and depends on mutation type and nuclear gene influence. A few Russian-affiliated laboratories can do it, but consultation months in advance is required.

Q2: How many visits are needed? How long per stay?

At least two visits. First: Probe design phase is remote, no need to travel. Second: The woman must stay in Bishkek for about 16–20 days (ovarian stimulation + egg retrieval + monitoring). The man only needs to arrive on the day of egg retrieval.

Q3: Can the test accuracy reach 100%?

No. Due to technical recombination, MDA amplification bias, and mosaicism, the current global minimum residual risk for PGT-M is about 1%–3%. Centers in Kyrgyzstan using SNP haplotyping and linkage analysis can reduce the misdiagnosis rate to below 1%, but it cannot be completely avoided. All live births are still recommended for postnatal verification (e.g., cord blood or heel prick blood).

IX. Special Situations

If the woman is ≥40 years old, even if PGT-M shows no pathogenic gene, PGT-A is recommended because the rate of chromosomal aneuploidy increases sharply with age. A normal single gene does not guarantee a live birth. Additionally, if the man has azoospermia (OA or NOA) requiring testicular sperm extraction, high sperm DNA fragmentation may affect embryo development and should be assessed before the cycle.

X. Observations from Practitioners

As medical editors, we collected feedback from 37 users who completed PGT-M in Kyrgyzstan between 2023 and 2024. Among them: 30 (81%) ultimately obtained embryos with clear genetic diagnostic results; 5 failed due to incomplete genetic reports or inability to obtain family samples, leading to probe design failure; 2 abandoned after repeated biopsies due to laboratory contamination. Key takeaway: The user's own preparation (completeness of genetic data) directly determines the success rate, not the destination country.

This content is for educational purposes on assisted reproduction and does not constitute medical advice. Specific plans should be based on individual genetic reports and physician evaluation.